LGR5 and neoplasm: Because LGR5 is a target of Wnt/β-catenin signaling that occurs during the adenoma–carcinoma sequence in CRC, LGR5 expression in MMR-P cases, which may involve the adenoma–carcinoma sequence, may be higher than that in MMR-D cases, which may involve the serrated neoplasia pathway [25].